Available for treatment of early stage breast cancer, endometrial cancer, and skin cancer, the Axxent eBx System is also FDA cleared for use in the treatment of surface cancers or conditions where radiation therapy is indicated, including IORT (intraoperative radiation therapy). As a platform technology, the Axxent System is designed to deliver non-radioactive therapy directly to cancerous tissue with minimal radiation exposure to surrounding healthy tissue. Utilizing a proprietary miniaturized X-ray source and robotic controller, treatment can be performed in minimally shielded therapeutic settings allowing the radiation oncologist and other medical personnel to be present during treatment delivery and minimizing patient anxiety.

"Innovations such as Electronic Brachytherapy can clearly support Premier's goals of improving healthcare quality and affordability, and we look forward to working with Premier's members to improve access to this safe effective cancer treatment that can be delivered in a more patient friendly environment than traditional isotope-based therapies that require shielded rooms," Klein added.

SOURCE Xoft, Inc.